Skip to main content
Erschienen in: Molecular Cancer 1/2018

Open Access 01.12.2018 | Letter to the Editor

A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer

verfasst von: Angela Grassi, Lisa Perilli, Laura Albertoni, Sofia Tessarollo, Claudia Mescoli, Emanuele D. L. Urso, Matteo Fassan, Massimo Rugge, Paola Zanovello

Erschienen in: Molecular Cancer | Ausgabe 1/2018

Abstract

Up to 20% of colorectal cancer (CRC) node-negative patients develop loco-regional or distant recurrences within 5 years from surgery. No predictive biomarker able to identify the node-negative subjects at high risk of relapse after curative treatment is presently available.
Forty-eight localized (i.e. stage I-II) colon cancer patients who underwent radical tumor resection were considered. The expression of five miRNAs, involved in CRC progression, was investigated by qRT-PCR in both tumor tissue and matched normal colon mucosa.
Interestingly, we found that the coordinate deregulation of four miRNAs (i.e. miR-18a, miR-21, miR-182 and miR-183), evaluated in the normal mucosa adjacent to tumor, is predictive of relapse within 55 months from curative surgery.
Our results, if confirmed in independent studies, may help to identify high-risk patients who could benefit most from adjuvant therapy. Moreover, this work highlights the importance of extending the search for tissue biomarkers also to the tumor-adjacent mucosa.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12943-018-0770-8) contains supplementary material, which is available to authorized users.
Abkürzungen
AUC
Area under ROC curve
CRC
Colorectal cancer
miRNA
microRNA
RFS
Recurrence-free survival

Background

Colorectal cancer (CRC) is the third most common tumor in the United States [1]. Up to 20% of node-negative (stage I and stage II) patients develop loco-regional or distant recurrences within 5 years from wide surgical resection and anastomosis. No predictive biomarker able to identify the node-negative subjects at high risk of relapse after curative surgery is presently available. Adjuvant chemotherapy is considered for stage II patients with at least one of the following clinical characteristics: sampling of fewer than 12 lymph nodes during surgical resection; poorly differentiated tumor; vascular, lymphatic or perineural invasion; tumor presentation with obstruction or tumor perforation and pT4 stage [2]. In this setting, the identification of biomarkers to guide adjuvant therapy decision could be extremely useful for clinical practice.
CRC develops and progresses through the accumulation of alterations affecting both noncoding and coding RNAs. Noncoding RNAs control multiple biological processes and have emerged as possible biomarkers for the clinical diagnosis and prognosis of CRC [3]. Different microRNA (miRNA) expression patterns observed in primary CRC have also been associated with tumor stage and patient survival [4].
In previous work, we identified up- and down-regulated miRNAs in primary colon carcinoma versus normal colon mucosa samples from metastatic CRC patients and reconstructed putative post-transcriptional regulatory sub-networks involving the most differentially expressed miRNAs and their target genes [5].
More recently, a study by Sanz-Pamplona and colleagues demonstrated that a number of tumor-related genes were activated in the tumor-adjacent non-neoplastic mucosa of CRC patients. These activated genes were enriched in transcription factors, indicating the existence of a transcriptional program driving the observed altered expression pattern in normal mucosa [6]. This result paves the way for the possibility to detect tumor-specific alterations also in the adjacent mucosa.
The focus of this paper is to identify miRNAs that could serve as biomarkers of relapse after resection in localized colon cancer, by investigating both matched normal colon mucosa and tumor tissue, resected from the surgical specimen.

Findings

In this study we explored the usefulness of a set of five miRNAs (i.e. miR-18a, miR-21, miR-182, miR-183 and miR-139) as biomarkers of relapse after primary tumor resection in stage I-II colon cancer.
These miRNAs were already known to be involved in CRC progression. In particular, miR-21 is a known oncomiR, whose high expression levels have been related to inflammation-associated colorectal tumorigenesis and dismal clinical outcome [7]. MiR-18a was found to be significantly up-regulated in patients with a form of chronic inflammation, i.e. colonic polyps [8], and it has been suggested as a prognostic factor for survival of post-operative CRC patients [9]. The increased expression of miR-183 and miR-182, both members of miR-183 cluster, has been related to advanced clinical stage, lymph node involvement, distant metastases and poor prognosis [10, 11]. Concerning miR-139, a recent study highlighted its down-regulation in colon cancer cell lines and patients and its association with metastasis and drug resistance [12].

Differentially expressed microRNAs in localized colon cancer between tumor and matched normal mucosa

Forty-eight patients with sporadic stage I-II colon cancer were considered and both tumor tissue and matched normal mucosa were collected at the time of curative surgery, see Additional file 1. The expression levels of the five selected miRNAs, already known to be modulated in advanced CRC (stage IV), were evaluated. Interestingly, our analysis confirmed that they were all significantly regulated in the early phases of the CRC tumor process. Specifically, miR-18a, miR-21, miR-182 and miR-183 were strongly up-regulated (p < < 0.001) in cancer tissue with respect to normal mucosa, whereas miR-139 was strongly down-regulated (p < < 0.001), see Fig. 1. This finding extends to stage I-II CRC the results previously obtained in stage IV CRC [5], showing that these five miRNAs accompany the CRC tumor process, from initial stages to advanced tumorigenesis.
To assess the role of tumor-associated inflammation in the modulation of these miRNAs, we also evaluated their expression levels in 10 patients affected by ulcerative colitis, a form of inflammatory bowel disease characterized by chronic and widespread inflammation of the colorectal mucosa. MiR-18a and miR-21 appeared weakly up-regulated in the inflammatory tissue vs. normal mucosa with p-value of 0.053 and 0.042, respectively. Conversely, miR-182, miR-183 and miR-139 were not significantly modulated (Additional file 1: Fig. S1). Although with a limited sample size, our data indicate that the modulations of miR-182, miR-183 and miR-139 are more specific of the tumor process. MiR-18a and miR-21, instead, appear weakly up-regulated also in inflamed bowel tissue, in line with previously published works [7, 8], thus suggesting that the strong up-regulation of these two miRNAs in the tumor tissue could be partially related to inflammation.

miRNA ratios as possible biomarkers of relapse

Based on recurrence-free survival (RFS), the 48 localized colon cancer patients in study were subdivided into a recurrent group (R, 23 patients with RFS > 55) and a non-recurrent group (NR, 25 patients with RFS < 55), see Additional file 1. The clinical characteristics of the patients are described in Table 1.
Table 1
Clinical characteristics of relapsing (R) and non-relapsing (NR) patients
Characteristics
 
R
NR
n = 23
n = 25
Age at resection (years)
Median
72
69
 
Range
55–85
50–90
Sex
M
16 (70%)
10 (40%)
 
F
7 (30%)
15 (60%)
Tumor site
Cecum, colon ascending, hepatic (right) flexure
7
6
 
transverse colon
3
4
 
Splenic (left) flexure, colon descending, sigmoid colon
13
15
 
Rectum
0
0
TNM stage
I
6
7
 
II
17
18
T(n)
T1
2
1
 
T2
4
6
 
T3
15
18
 
T4
2
0
N(n)
N0
23(100%)
25(100%)
M(n)
M0
23 (100%)
25 (100%)
Grading (n)
G1
5
4
 
G2
15
17
 
G3
3
4
 
G4
0
0
To investigate whether the selected miRNAs could be useful to predict tumor relapse, we applied the miRNA ratio approach [13, 14]. We calculated 10 ratios between the expression values of all possible miRNA pair combinations (see Additional file 1) in both the tumor tissue and the adjacent normal mucosa, and assessed their capability to predict relapse through univariate logistic regression analysis, Additional file 1: Table S1. None of the miRNA ratios resulted predictive when evaluated in the colon cancer tissue. Three miRNA ratios, evaluated in the tumor-adjacent mucosa, were found to be significant predictors of relapse within 55 months from resection: miR-21/miR-183 (p = 0.0011), miR-18a/miR-182 (p = 0.0053) and miR-18a/miR-183 (p = 0.0099), see Fig. 2a and Additional file 1: Table S2 for details about univariate logistic regression models. Corresponding areas under ROC curves were 0.83, 0.76 and 0.78, respectively, see Fig. 2b. It is noteworthy that the three significant miRNA ratios (miR-21/miR-183, miR-18a/miR-182 and miR-18a/miR-183) together with miR-21/miR-182 ratio, which appears weakly significant (p = 0.063, Additional file 1: Table S1), share a common characteristic. These miRNA ratios have at numerator a microRNA that in our setting appears associated also to inflammation (either miR-18a or miR-21) and at denominator a microRNA more specific of the tumor (either miR-183 or miR-182). We thus conclude that a coordinate deregulation of these two couples of miRNAs may be a useful predictor of relapse. To investigate how the individual miRNAs perform as predictive biomarkers, an additional univariate logistic regression analysis was executed and reported in Additional file 1: Table S3, showing that the miRNA ratio approach yields to more significant results. Moreover, a bivariate logistic regression analysis, taking as covariates all the possible combinations of miRNA pairs, was conducted (Additional file 1: Table S4). This analysis confirmed that, regardless of the chosen approach, it is the coordinated alteration of the two couples of miRNAs that we have identified to be predictive of relapse. The advantage of the miRNA ratio approach is to overcome the need for miR-200c as a normalizer.
More interestingly, the three significant miRNA ratios seem to be potential biomarkers when evaluated in the adjacent, morphologically normal, mucosa and not in the tumor tissue. This result, apparently counterintuitive, is in line with recent gene expression studies on the adjacent mucosa conducted both in CRC [6] and in head and neck cancer [15]. Indeed, it is emerging with increasing evidence that the crosstalk between tumor and microenvironment could also affect the adjacent mucosa and that also this tissue may be informative.

Conclusion

Our analysis showed that not a single miRNA, but rather a coordinated alteration of four miRNAs (i.e. miR-18a, miR-21, miR-182 and miR-183) may be useful to predict recurrence after curative surgery. This is the first study that outlines a predictive role of miRNAs, evaluated in the adjacent, morphologically normal, mucosa of CRCs. Our results, if confirmed in an ample cohort of patients, may help to identify among localized colon cancer (stage I-II) patients those at high risk of relapse who could benefit most from adjuvant therapy.

Acknowledgements

The authors thank Alberto Amadori and Donna M. D’Agostino for critical reading of the paper.

Funding

This study was supported by funds from AIRC IG 2013 (n. 14256), University of Padova (PRAT 61842) and IOV 5 × 1000 Intramural Research Grant 2015 ‘miR-182 as possible biomarker of CRC progression’ to P. Zanovello.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.
The study was approved by the Ethics Committee of the University Hospital of Padua (n. 57841 December 3rd 2013) and informed consent was obtained from all the patients involved.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRefPubMed Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.CrossRefPubMed
2.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72.CrossRefPubMed Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64–72.CrossRefPubMed
3.
Zurück zum Zitat Ragusa M, Barbagallo C, Statello L, Condorelli AG, Battaglia R, Tamburello L, et al. Non-coding landscapes of colorectal cancer. World J Gastroenterol. 2015;21(41):11709–39.CrossRefPubMedPubMedCentral Ragusa M, Barbagallo C, Statello L, Condorelli AG, Battaglia R, Tamburello L, et al. Non-coding landscapes of colorectal cancer. World J Gastroenterol. 2015;21(41):11709–39.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Slattery ML, Herrick JS, Pellatt DF, Mullany LE, Stevens JR, Wolff E, et al. Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget. 2016;7(37):60193–205.CrossRefPubMedPubMedCentral Slattery ML, Herrick JS, Pellatt DF, Mullany LE, Stevens JR, Wolff E, et al. Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget. 2016;7(37):60193–205.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 2013;14:589.CrossRefPubMedPubMedCentral Pizzini S, Bisognin A, Mandruzzato S, Biasiolo M, Facciolli A, Perilli L, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics. 2013;14:589.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi DG, Crous-Bou M, Sole X, et al. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer. 2014;13:46.CrossRefPubMedPubMedCentral Sanz-Pamplona R, Berenguer A, Cordero D, Mollevi DG, Crous-Bou M, Sole X, et al. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer. 2014;13:46.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016;22(15):3841–8.CrossRefPubMedPubMedCentral Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, et al. MicroRNA MIR21 (miR-21) and PTGS2 expression in colorectal cancer and patient survival. Clin Cancer Res. 2016;22(15):3841–8.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Zekri AR, Youssef AS, Lotfy MM, Gabr R, Ahmed OS, Nassar A, et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS One. 2016;11(5):e0154130.CrossRefPubMedPubMedCentral Zekri AR, Youssef AS, Lotfy MM, Gabr R, Ahmed OS, Nassar A, et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS One. 2016;11(5):e0154130.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34(4):1069–75.PubMed Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34(4):1069–75.PubMed
10.
Zurück zum Zitat Zhou T, Zhang GJ, Zhou H, Xiao HX, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2014;26(2):229–33.CrossRefPubMed Zhou T, Zhang GJ, Zhou H, Xiao HX, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2014;26(2):229–33.CrossRefPubMed
11.
Zurück zum Zitat Tang S, Wu WK, Li X, Wong SH, Wong N, Chan MT, et al. Stratification of digestive cancers with different pathological features and survival outcomes by MicroRNA expression. Sci Rep. 2016;6:24466.CrossRefPubMedPubMedCentral Tang S, Wu WK, Li X, Wong SH, Wong N, Chan MT, et al. Stratification of digestive cancers with different pathological features and survival outcomes by MicroRNA expression. Sci Rep. 2016;6:24466.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, et al. miR-139-5p inhibits the epithelial-Mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by Downregulating BCL2. Sci Rep. 2016;6:27157.CrossRefPubMedPubMedCentral Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, et al. miR-139-5p inhibits the epithelial-Mesenchymal transition and enhances the chemotherapeutic sensitivity of colorectal cancer cells by Downregulating BCL2. Sci Rep. 2016;6:27157.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–8.CrossRefPubMedPubMedCentral Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, et al. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362–6.CrossRefPubMedPubMedCentral Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, et al. A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 2016;114(12):1362–6.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Raudenska M, Sztalmachova M, Gumulec J, Fojtu M, Polanska H, Balvan J, et al. Prognostic significance of the tumour-adjacent tissue in head and neck cancers. Tumour Biol. 2015;36(12):9929–39.CrossRefPubMed Raudenska M, Sztalmachova M, Gumulec J, Fojtu M, Polanska H, Balvan J, et al. Prognostic significance of the tumour-adjacent tissue in head and neck cancers. Tumour Biol. 2015;36(12):9929–39.CrossRefPubMed
Metadaten
Titel
A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer
verfasst von
Angela Grassi
Lisa Perilli
Laura Albertoni
Sofia Tessarollo
Claudia Mescoli
Emanuele D. L. Urso
Matteo Fassan
Massimo Rugge
Paola Zanovello
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Molecular Cancer / Ausgabe 1/2018
Elektronische ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-018-0770-8

Weitere Artikel der Ausgabe 1/2018

Molecular Cancer 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.